6:49 PM · 24 February 2021

J&J single-shot Covid vaccine nears FDA approval

J&J
Stocks
JNJ.US, Johnson & Johnson
-
-

Johnson & Johnson (JNJ.US) stock rose 1.5% after the U.S. FDA endorsed the drugmaker's one-shot Covid-19 vaccine which appeared safe and effective in trials. New data showed the vaccine was 64% effective at stopping moderate to severe cases of COVID-19 after 28 days in thousands of trial participants in South Africa where a new variant has swept across the country. Overall, the vaccine was 100% effective at stopping hospitalization 28 days after vaccination, compared with 85% at 14 days, and there were no COVID-19 deaths among those who received the shot rather than a placebo. FDA’s Vaccines and Related Biological Products Advisory Committee, will meet on Friday to review company's request for emergency use authorization.

Johnson & Johnson (JNJ.US) stock bounced off the lower limit of the ascending channel which coincides with 50 SMA (green line) and support at $160.23. If the current sentiment prevails, upward move could be extended to the $167.77 handle or even $173.71 handler where all-time high is located. Source: xStation5
15 October 2025, 5:10 PM

TSMC Earnings Preview: Will the Key Semiconductor Supplier Surprise the Market?

15 October 2025, 3:05 PM

US Open: American Indices Rally on Anticipated End of Fed Balance Sheet Reduction

15 October 2025, 2:53 PM

Bank of America, Wells Fargo, and Morgan Stanley: Q3 2025 Earnings Overview

15 October 2025, 1:24 PM

Abbott reports no surprises in Q3, but tariff risks and lowered forecasts drag the share price down💡

Join over 1 700 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits